Frequently Asked Questions
In 2022, the global anti-inflammatory medicines market is expected to be worth USD 100.9 billion.
The market for anti-inflammatory drugs is estimated to increase at a 9.80% CAGR between 2023 and 2030, reaching USD 194.1 billion in 2030.
Nonsteroidal anti-inflammatory drugs (NSAIDs) led the market in 2022, accounting for 68% of the total.
The respiratory diseases segment contributes the rest to the demand for anti-inflammatory drugs.
In the anti-inflammatory drugs market, the injection sector has the highest CAGR.
Asia Pacific is fueling the growth of the anti-inflammatory drugs industry, with over one-third share in 2022.
Other important participants include Pfizer Inc., Novartis AG, GlaxoSmithKline plc, and Amgen Inc., as well as AbbVie Inc, Merck & Co., Inc, and Bristol-Myers Squibb Company.
The prevalence of inflammation-related illnesses and potential pipeline candidates is raising are the major market drivers.
Side effects of NSAIDs, stringent regulatory requirements, and generic competition are the major market restraints.
Biotechnology Advances and novel anti-inflammatory medications are being introduced are the major opportunities in the anti-inflammatory drugs industry.